ACADIA Pharmaceuticals Inc (ACAD)vsRegeneron Pharmaceuticals Inc (REGN)
ACAD
ACADIA Pharmaceuticals Inc
$21.56
-0.74%
HEALTHCARE · Cap: $3.61B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1262% more annual revenue ($14.92B vs $1.10B). ACAD leads profitability with a 34.3% profit margin vs 29.6%. REGN appears more attractively valued with a PEG of 1.05. REGN earns a higher WallStSmart Score of 64/100 (C+).
ACAD
Buy54
out of 100
Grade: C-
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACAD.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 30 in profit
Keeps 34 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Earnings declined 81.8%
Operating margin of -1.7%
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACAD
The strongest argument for ACAD centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 34.3% and operating margin at -1.7%.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ACAD
The primary concerns for ACAD are PEG Ratio, EPS Growth, Operating Margin.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ACAD profiles as a mature stock while REGN is a growth play — different risk/reward profiles.
ACAD carries more volatility with a beta of 0.83 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 54/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ACADIA Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?